Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.02, $0.04 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $90.55 million versus the consensus estimate of $92.5 million.

GUIDANCE:

Ironwood Pharma sees FY2025 revenue of $260-290 million, versus the consensus of $287.6 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Barclays Starts Zurn Water Solutions (ZWS) at Overweight
• Baird Downgrades Alpine Income Property Trust (PINE) to Neutral